Clinical Trial

Medicure Reports Financial Results For Quarter Ended September 30, 2024

WINNIPEG, MB / ACCESSWIRE / November 25, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused…

1 year ago

Hemostemix Announces ACP-01 Treatment-Purchase Available with Social Media Campaign Underway

Calgary, Alberta--(Newsfile Corp. - November 25, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")…

1 year ago

Seven Top Pharma Companies Adopt PhaseV’s Machine Learning Technology for Drug Development

Within Two Years of Hitting the Market, PhaseV Solutions are Being Used to Guide Adaptive Trials, Precision Medicine, and Indication…

1 year ago

Slope and LabConnect Unveil Groundbreaking Bidirectional API Integration for Clinical Trials

First-of-its-kind API integration revolutionizes biospecimen lifecycle management and data integrity RICHMOND, Va. and JOHNSON CITY, Tenn., Nov. 25, 2024 /PRNewswire/…

1 year ago

Xenon to Showcase New Long-Term Azetukalner Data at AES 2024

Five posters to be presented including new long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in FOS…

1 year ago

Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

TN-401 AAV9-based Gene Therapy Designed to Deliver Fully Functional PKP2 Gene with the Aim of Increasing Protein Levels to Address…

1 year ago

CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology

VANCOUVER, Washington, Nov. 25, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing…

1 year ago

Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns

HAIFA, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a biotechnology…

1 year ago